BioSpace News Archive

Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral therapy for the treatment of acromegaly

Oncology Pharma Inc. (OTC: ONPH): Today, the company announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization.

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million, Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Judith Varner, Ph.D., as a scientific advisor to the company. Dr. Varner currently serves as Professor in the Departments of Pathology and Medicine at the Moores Cancer Center at the University of California, San Diego (UCSD).

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that it plans to release its fourth quarter and full year financial results after the market closes on Wednesday, March 24, 2021.

Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial public offering of shares of its common stock. Gain is offering 3,636,364 shares of its common stock. The initial public offering price is expected to be between $10.00 and $12.00 per share, before underwriting discounts and commissions.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that CEO Faz Chowdhury, Ph.D. will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.

- New Initiative is part of I-Mab’s long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology platforms to develop novel drug molecules - I-Mab continues to focus on delivering on key clinical programs while building pipeline of next generation assets

Hollister Incorporated, an independent, employee-owned company that develops, manufactures, and markets healthcare products worldwide has launched the Infyna Chic™ intermittent catheter, the latest in the company’s line of hydrophilic catheter products, to the US market.

DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence subject enrollment in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002).